North Carolina Headlines

DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight 2026” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Small Cell Lung Cancer Pipeline Report @ https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight

Key Takeaways from the Small Cell Lung Cancer Pipeline Report

• On June 15, 2026- AbbVie conducted a study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future).
• On June 12, 2026- Merck Sharp & Dohme LLC initiated a phase 1b/2 study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread.
• On June 11, 2026- AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type and with PD-L1 high expression (PEARL).
• DelveInsight’s Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Small Cell Lung Cancer treatment.
• The leading Small Cell Lung Cancer Companies such as Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee’s Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others.
• Promising Small Cell Lung Cancer Pipeline Therapies such as Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide and others.

Access DelveInsight’s in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Small Cell Lung Cancer Clinical Trials and Studies

Small Cell Lung Cancer Overview

Small cell lung cancer is fast-growing lung cancer that develops in the tissues of the lungs. It is the least common type of lung cancer and characterized by rapid, uncontrolled growth of certain cells in the lungs. Small cell lung cancer (SCLC), previously known as oat cell carcinoma, is considered distinct from other lung cancers, which are called non–small cell lung cancers (NSCLCs) because of their clinical and biologic characteristics. Small cell lung carcinoma (SCLC) arises in peribronchial locations and infiltrates the bronchial submucosa.

Small Cell Lung Cancer Emerging Drugs Profile

• AMG 757: Amgen

AMG 757 is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in Phase I clinical studies for the treatment of prostate cancer and Small cell lung cancer.

• APG-1252: Ascentage Pharma

APG-1252 is a highly potent, small-molecule based Bcl-2 family protein inhibitor drug. APG-1252 is designed to treat SCLC, NSCLC, lymphoma, and other solid tumors by selectively blocking Bcl-2 and Bcl-xL to restore the apoptosis process. The drug is in Phase I/II clinical studies for the treatment of SCLC.

The Small Cell Lung Cancer Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Small Cell Lung Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Small Cell Lung Cancer Treatment.
• Small Cell Lung Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Small Cell Lung Cancer market.

Get a detailed analysis of the latest innovations in the Small Cell Lung Cancer Pipeline @ Small Cell Lung Cancer Unmet Needs

Small Cell Lung Cancer Companies

Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee’s Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others.

Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Small Cell Lung Cancer Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies @ Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Small Cell Lung Cancer Pipeline Report

• Coverage- Global
• Small Cell Lung Cancer Companies- Ascentage Pharma, Merck & Co, AstraZeneca, Advenchen Laboratories, GlaxoSmithKline, Advanced Accelerator Applications, Trillium Therapeutics, Vernalis, Oncoceutics, NewBio Therapeutics, Wigen Biomedicine, Linton Pharm, Carrick Therapeutics, Xencor, Jiangsu HengRui Medicine, Aileron Therapeutics, Roche, Ipsen, Celgene, Lee’s Pharmaceutical Limited, AbbVie, G1 Therapeutics, Chipscreen Biosciences, Luye Pharma Group, Shanghai Henlius Biotech, CSPC ZhongQi Pharmaceutical Technology, Impact Therapeutics and others.
• Small Cell Lung Cancer Pipeline Therapies- Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, AL8326, Durvalumab, Lurbinectedin, Pembrolizumab, Etoposide and others.
• Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive Pipeline Report @ Small Cell Lung Cancer Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Small Cell Lung Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Small Cell Lung Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Pembrolizumab: Merck & Co
11. Mid Stage Products (Phase II)
12. Dostarlimab: GlaxoSmithKline
13. Early Stage Products (Phase I)
14. AMG 757: Amgen
15. Preclinical/Discovery Stage Products
16. S 055746: Vernalis
17. Inactive Products
18. Small Cell Lung Cancer Key Companies
19. Small Cell Lung Cancer Key Products
20. Small Cell Lung Cancer- Unmet Needs
21. Small Cell Lung Cancer- Market Drivers and Barriers
22. Small Cell Lung Cancer- Future Perspectives and Conclusion
23. Small Cell Lung Cancer Analyst Views
24. Small Cell Lung Cancer Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/small-cell-lung-cancer-pipeline-insight